Pharvaris (PHVS) Cash & Equivalents (2019 - 2026)

Pharvaris (PHVS) has 8 years of Cash & Equivalents data on file, last reported at $289.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 16.22% year-over-year to $289.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $289.1 million (up 16.22% YoY) and the FY2025 annual result came in at $329.5 million, up 8.46% from the prior year.
• Cash & Equivalents eased to $289.1 million in Q1 2026, from $339.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $420.9 million in Q4 2023 to a low of $145.1 million in Q1 2023.
• A 5-year average of $272.1 million and a median of $248.8 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 175.79% — and 2025, when it slumped 38.94%.
• Tracing PHVS's Cash & Equivalents over 5 years: stood at $165.1 million in 2022, then surged by 154.94% to $420.9 million in 2023, then declined by 28.73% to $300.0 million in 2024, then rose by 13.18% to $339.5 million in 2025, then fell by 14.84% to $289.1 million in 2026.
• The last three Cash & Equivalents figures came in at $289.1 million (Q1 2026), $339.5 million (Q4 2025), and $385.0 million (Q3 2025), per Business Quant data.